

1

2 Diagnostic Utility of Electrophysiological Markers for Early and 3 Differential Diagnosis of Alzheimer's, Frontotemporal, and Lewy 4 Body Dementias: A Systematic Review

5 *Stéphanie De Keulenaer¹, Sara Van Mossevelde^{1,2}, Tobi Van den Bossche^{1,2}, David Crosiers^{1,2}, Patrick Cras^{1,2,3}, Tommas
6 Ellender¹, Rose Bruffaerts^{1,2}*

7 ¹ University of Antwerp (Uantwerpen), Belgium
8 ² University Hospital of Antwerp (UZA), Belgium
9 ³ IBB-Neurobiobank, Antwerp, Belgium

10

11

12

Abstract

13 *Background*

14 An early and accurate diagnosis is crucial to provide optimal patient care in neurodegenerative
15 diseases. Although an EEG shows advantages in availability and cost compared to the current
16 diagnostic tools, it is not routinely used in clinical practice. Previous reviews have either focused on
17 single disease populations and/or solely on resting state EEG. To evaluate the utility of EEG for early
18 diagnosis and differential diagnosis, we conducted a systematic review across Alzheimer's disease
19 (AD), Frontotemporal Dementia (FTD) and Lewy Body Dementia (DLB).

20 *Methods*

21 We searched databases Pubmed, Cochrane, Web of Science, and Scopus for articles published from
22 2000 to 2023 investigating resting-state and task-based EEG-markers in biomarker-proven AD, FTD
23 and DLB.

24 *Results*

25 Our search yielded a total of 12010 studies, of which 71 papers were eligible: 34 on AD, 18 on DLB
26 and 9 on FTD. Slowing of the frequency spectrum was a common observation across diseases,
27 achieving excellent sensitivity in AD and DLB. Research on FTD was limited and with varying results
28 in the discrimination from healthy controls, although connectivity analysis and microstates are
29 promising avenues. In differential diagnosis, both spectral and connectivity metrics show encouraging
30 results. Task-based EEG emerges as a promising tool in early AD.

31

32 *Conclusion*

33 EEG shows promise as a cost-effective, non-invasive tool for early detection and differential
34 diagnosis. Future research should aim to collect standardized data from multicentric cohorts, across
35 multiple diseases and stages, and explore the neural underpinnings of these diseases, to improve
36 interpretability of the findings.

37 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

38

Introduction

39 The estimated global prevalence of dementia in 2019, 57.4 million cases, is predicted to show a 166%
40 increase by 2050 due to population growth and ageing [1]. Alzheimer's Disease (AD) is the most
41 common type, representing 60-70% of dementia cases, followed by Frontotemporal Dementia (FTD)
42 and Lewy Body Dementia (DLB). One of the critical challenges in dementia, is an early and accurate
43 diagnosis of neurodegenerative disease. Early detection is crucial for management of the disease and
44 the effectiveness of disease-modifying therapies [2]. However, several issues complicate diagnostic
45 accuracy. First, conventional structural diagnostic tools such as magnetic resonance imaging (MRI)
46 and computer tomography (CT) are not sensitive to metabolic and functional alterations in the brain,
47 occurring years before clinical onset ([3]). Second, traditional diagnostic tools are lacking in disease
48 specificity, in particular when faced with syndromes high in clinical overlap. Last, cerebrospinal fluid
49 (CSF) biomarkers and positron emission tomography (PET) scans, are valuable in providing insights
50 in underlying pathology but are costly, invasive and not widely-accessible. As an alternative,
51 electroencephalography (EEG) has emerged as a non-invasive, widely-accessible and cost-effective
52 tool in the search for reliable biomarkers. EEG measures neuronal activity at high temporal resolution,
53 allowing detection of early functional changes associated with ageing and neurodegeneration,
54 delivering unique insights in the effects of neuropathology on neurophysiological mechanisms
55 underpinning cognitive functioning.

56 In AD, the utility of resting state EEG (rsEEG) rhythms in wakefulness (eyes open or eyes closed)
57 have been studied as candidate biomarkers, as they are non-invasive, cost-effective and do not require
58 the performance of tasks, tackling problems with fatigue and motivation. Compared to healthy
59 controls (HC), AD patients show slowing, i.e. the leftward shift in the power spectrum from higher (α ,
60 β , and γ) towards lower frequencies(δ and θ), as well as alterations in connectivity, complexity and
61 synchronization of neural activity [4]. An alternative approach is task-based EEG, providing insights
62 into the amplitude and latency of neural responses or event-related potentials (ERP) elicited by
63 different cognitive tasks. A recent systematic review highlights reduced amplitude and delayed latency
64 in AD compared to healthy controls in various well-known ERP components such as the P300 and
65 N400 [5]. However, heterogeneity in the AD samples and study paradigms, along with scarcity of
66 reported effect sizes, complicates meta-analyses across both resting-state EEG [4] as task-based EEG
67 studies [5]. Furthermore, diagnostic criteria have advanced from traditional neuropsychological and
68 clinical measures to the inclusion of biomarkers, improving diagnostic accuracy in research studies
69 and enhancing the reliability of research outcomes.

70 Another issue is the differential discrimination between neurodegenerative diseases. The differential
71 diagnosis in early stages is suboptimal, for instance in discriminating DLB from AD. In the most
72 recent consortium on diagnostic criteria, posterior slow-wave activity showing periodic fluctuations
73 within the pre- α/θ range in resting-state EEG was recognized as a supportive biomarker for DLB [6].
74 From a recent systematic review, over 90% of DLB patients have diffuse EEG abnormalities [7].
75 Although EEG slowing was found to be more severe in AD compared to DLB, EEG abnormalities
76 related to DLB overlap with those found in other neurodegenerative diseases such as AD. Just as in
77 AD studies, previous systematic reviews in DLB have addressed issues such as preliminary sample
78 sizes with large heterogeneity in patient cohorts, and lack of standardization in EEG protocols and
79 reporting, complicating the identification of the optimal feature for differential diagnosis [7, 8]

80
81 In FTD research, studies have pursued similar aims of improving diagnosis with EEG, showing
82 slowing of the power spectrum [9, 10]. However, the scarcity of studies in FTD results in too little
83 evidence to reach consensus.

84
85 Although numerous studies have been conducted on the use of EEG in AD, FTD and DLB, no
86 comprehensive review has yet compared EEG results across neurodegenerative diseases. Addressing
87 this gap is crucial to define the specificity of electrophysiological markers in the differential diagnosis.

88 Additionally, to evaluate the utility of EEG in early stages of the diseases, we are interested in the
89 preclinical and prodromal stages of the diseases. In line with the current diagnostic standards, we
90 include exclusively biomarker-proven stages of AD [11]. To summarize the available literature, we
91 conducted a systematic search on publications studying EEG-markers across AD, FTD, DLB and/or
92 their preclinical and prodromal phases, compared to healthy controls.

93
94

Methods

95 The review was prospectively registered in PROSPERO (ID: CRD42023392253). We performed a
96 systematic search using online databases Pubmed, Cochrane, Web of Science and Scopus for English
97 articles published from 2000 to January 2023. The full search strategy is provided in supplementary
98 material (S1).

99

100 *Screening*

101 Our search yielded a total of 12010 studies. The online collaboration platform Rayyan
102 (<https://www.rayyan.ai/>) was used to implement, deduplicate and screen articles. Possible duplicates
103 as detected by Rayyan were manually checked. Following deduplication, 6952 abstracts were screened
104 for eligibility based on inclusion and exclusion criteria by two independent researchers (SDK, RB)
105 blinded to each other's rating. Based on abstract only, 6243 articles were excluded. The remaining 709
106 potential eligible articles were then screened on full text based on the same inclusion and exclusion
107 criteria. The main reason of exclusion was not including biomarkers in AD ($n=476$). Conflicts were
108 resolved by discussion between the researchers. The PRISMA flowchart (Figure 1) shows the full
109 screening and exclusion process.

110 Inclusion criteria:


- 111 - Participant population: AD, FTD, DLB, including preclinical and prodromal stages,
112 presymptomatic carriers of genetic causative mutations and healthy controls. In line with the
113 International Working Group 2 (IWG-2) criteria for AD, we only include biomarker-proven
114 cases of AD showing in vivo evidence of amyloid and tau pathology [12], presymptomatic
115 carriers of familial AD (FAD) by *Amyloid Precursor Protein (APP)* and *Presenilin*
116 (*PSEN1/PSEN2*) causative mutations were included. Criteria for FTD diagnosis were a
117 diagnosis following the Rascovsky criteria for bvFTD [13], Gorno-Tempini criteria for
118 PPA[14], carrier of a genetic mutation of FTD, and/or imaging evidence of frontotemporal
119 atrophy. DLB was defined by the criteria of McKeith [6, 15].
- 120 - Primary research studies
- 121 - English language
- 122 - Studies using resting-state EEG and/or task-based EEG as neuroimaging modality

123 Exclusion criteria:

- 124 - Studies that combine multiple neuroimaging modalities or EEG with other biomarkers but do
125 not separately report the performance of EEG markers.
- 126 - Animal studies
- 127 - Population with comorbidities (Down Syndrome, Schizophrenia, ...)
- 128 - Prognostic studies
- 129 - Case studies or study population <5 participants
- 130 - Sleep EEG

131 Lastly, risk of bias was assessed using a hybrid version of the Joanna Briggs Institute (JBI) Critical
132 Appraisal checklist (supplementary material S2).

133
134



168 **Figure 1.** PRISMA flowchart diagram for systematic reviews [16].

169 *Data extraction:*

170 The following data was extracted manually from eligible studies. Tables with data can be
171 found in supplementary material (S3).

- 172 1. Article information: First author, year
173 2. Study population: Sample size, patient population(s), control group(s), biomarkers
174 3. EEG acquisition: number of electrodes, sampling frequency, recording state
175 (resting/task-based), duration
176 4. Analysis
177 5. Reported results

178 *Data synthesis:*


179 As our field of interest includes a heterogenous group of pathologies and disease stages as
180 well as various recording and analysis conditions, data is presented descriptively. AUROC
181 characteristics, sensitivity, specificity and diagnostic accuracy were reported if provided.

182

Results

183 Study characteristics

184 Our search yielded a total of 6957 unique studies, of which 71 studies were included in the final
 185 review (figure 1). In total, we included 34 AD studies, 9 FTD studies, 18 DLB studies, and 9 studies
 186 combining disease populations. The studies included a total of 1115 patients with dementia due to
 187 biomarker-proven Alzheimer (demAD) and 915 prodromal AD (prodAD) cases. Seven studies
 188 included preclinical AD pathology by positive amyloid and/or tau biomarkers ($n=397$). Six studies
 189 included FAD ($n=43$) and/or prodromal FAD (prodFAD, $n=22$) and asymptomatic carriers of a PSEN
 190 1 or APP mutation (AcrFAD, $n=100$). Four studies included patients with bvFTD ($n=108$), three
 191 studies included not specified FTD ($n=38$). One study included familiar CHMP2B-FTD symptomatic
 192 ($n=5$) and presymptomatic carriers ($n=5$). One study compared non-fluent variant PPA ($n=18$),
 193 semantic variant PPA ($n=10$) and logopenic variant PPA ($n=12$). 18 studies included DLB patients
 194 ($n=589$), while only one study focused on prodDLB ($n=21$). In case studies included DLB or FTD
 195 combined with non-biomarker proven AD, only the results of the FTD or DLB patients are described.
 196 Five studies compared prodAD ($n=111$) and prodDLB ($n=111$), while one study included demAD
 197 ($n=66$) and DLB ($n=66$). Two studies using the same dataset compared PPA ($n=5$), bvFTD ($n=13$) and
 198 prodAD ($n=18$), a third study compared bvFTD ($n=48$) to AD ($n=69$). The majority of the studies
 199 employed a rsEEG recording (figure 2c). All of studies combining different disease populations
 200 employed resting state EEG.



202

Figure 2. a) Study characteristics in studies including a single patient population. b) Study characteristics comparative studies. c) Percentage of studies using rsEEG or tbEEG per population. AD= Alzheimer's Disease, prodAD= prodromal AD, preAD=preclinical AD, FAD= Familial AD, prodFAD= prodromal FAD, Acr FAD= asymptomatic carriers of a FAD causative mutation, FTD= frontotemporal dementia, bvFTD= behavioral variant FTD, CHMP2B-FTD= symptomatic CHMP2B carriers, CHMP2B-FTD Acr= asymptomatic CHMP2B carriers, nfvPPA= non-fluent variant primary progressive aphasia (PPA), svPPA= semantic variant PPA, lvPPA= logopenic variant PPA, DLB= Dementia with Lewy Bodies, prodDLB= prodromal DLB, rsEEG= resting-state EEG. tbEEG= task-based EEG

203

208

209 *Potential for AD diagnosis*

210 *Resting state EEG*

211 Diffuse slowing of the frequency spectrum towards lower frequencies is a consistent observation in
212 both prodAD [17–20] and demAD [21, 22]. The shift in the power spectrum in demAD manifests as
213 reduced spectral metrics in the α band, while spectral power in θ band increases [22]. Smailovic found
214 that low α global field synchronization (GFS), a measure of global functional connectivity in the
215 frequency domain, is linked to abnormal A β 42 levels in demAD and prodAD, and high levels of p-tau
216 and t-tau in prodAD [23]. Secondly, in demAD, high levels of p-tau and t-tau correlate with low global
217 strength of scalp potential (GFP) in β and δ bands. In prodAD, high GFP in δ and θ was linked to
218 abnormal CSF levels of A β 42, while lower GFP α and β is linked to increased p-tau and t-tau. These
219 results are in line with the research of Cecchetti, showing that prodAD show higher θ density than
220 MCI without AD pathology with over 75% sensitivity and 70% specificity [21]. Similarly, Rodriguez
221 demonstrated that frontotemporal alterations in β band discriminate between presymptomatic PSEN1
222 carriers and noncarriers and between FAD and HC (see figure 3)[24]. Additionally, significant
223 progressive alterations in bispectral metrics are found along the AD continuum [25]. Specifically, with
224 increasing severity, interactions between the δ and θ bands and other bands increase, while interactions
225 with high frequency bands α , β 1, and β 2 bands diminish. Similarly, synchronization measures
226 demonstrate reduced functional connectivity in demAD in α and β bands, while coherence metrics in θ
227 band increase [26]. These results are similar to findings by Revilla-Vallejo, where Shannon Entropy
228 (SE) shows higher values in the δ band and lower values in the α and β 1 bands in prodAD and demAD
229 compared to HC, suggesting less connectivity and integration in these two bands [27].

230
231 Another way to look at resting-state activity is through microstate analysis. Spontaneous resting state
232 activity can be described using microstates, transient global patterns of scalp potential, reflecting
233 coordination of neural activity among networks [28]. Microstate analysis in AD reveals alterations in
234 the duration, occurrence and coverage of microstates varying with severity. Specifically, demAD
235 patients showed a longer duration in microstate B [29]. In the study of Smailovic, topographic
236 differences in microstates A and D were found between HC and patient populations SCD, prodAD and
237 demAD [30]. Furthermore, preclinical and prodromal AD could be differentiated from the dementia
238 stage by topographical differences in microstate A. The authors further found that topographical
239 alterations in microstate C were linked to increased A β 42 levels, while p-tau levels were linked to
240 microstate B alterations.

241
242 Recently, a number of studies used EEG-based machine learning classifiers for the detection of AD.
243 An advantage of these studies is that the outcome measures offer more insight into the potential
244 clinical implementation, which necessitates robust results at the individual level, compared to the prior
245 studies which reported results from group-level comparisons. Studies discriminating AD from HC
246 show promising classification accuracies in demAD ranging from 78% to 91% and in prodAD ranging
247 from 73-85% (see figure 3). Another measure of the model's accuracy is the F1 score, which is
248 calculated using precision (positive predictive value) and recall (true positive rate). Studies achieved
249 encouraging F1 scores ranging from 0.86 to 0.88 [31, 32]. Regarding the age factor, Durongbhan [33]
250 found encouraging results in discriminating demAD from HC below the age of 70 (sensitivity >90%,
251 specificity >83%), in individuals over 70 years, results were a little lower (>67% sensitivity, >85%
252 specificity). Zhao studied both linear and nonlinear synchronization and found age- and disease-related
253 differences in network synchronization [34]. Healthy individuals below 70 years old exhibit
254 widespread linear synchronization with dynamic variability between eyes closed (EC) and eyes open
255 (EO) states, while in young individuals with demAD, this dynamic variability is diminished, indicating
256 network dysfunction. Secondly, they found a high widespread nonlinear synchronization during EO
257 with higher dynamic variability compared to demAD. In individuals above 70, both HC and demAD
258 showed similar levels of linear and nonlinear synchronization with minimal variability between states.
259 Combining linear and nonlinear connectivity yields highest classification accuracies below the age of
260 70 (80.3% EO, 74.5% EC) and above the age of 70 (EO 86.5%, EC 90.5%).

261

262 In preAD, PSD patterns can be used to model compensatory mechanisms and progression to AD [35].
263 More specifically, individuals with amyloid burden in absence of neurodegeneration evidenced by
264 brain metabolism in AD core regions, show increased functional connectivity in the parieto-occipital α
265 band. In individuals with neurodegeneration, the impact on EEG metrics varies depending the degree
266 of amyloid accumulation. More specifically, surpassing a critical threshold of amyloid accumulation,
267 reverses the compensatory upregulation of higher β and γ frequencies and decreased δ power seen in
268 intermediate amyloid burden, resulting in decreased β and γ power, MSF, spectral entropy, complexity
269 and wSMI in θ band while δ power increases. In individuals with subjective complaints (SCD) with
270 amyloid burden, Shim observed similar patterns of increased δ power in parietal, occipital and
271 posterior cingulate regions combined with decreased α activity in fusiform and inferior temporal
272 areas[36]. In predicting AD pathology in individuals with SCD, the best ML model shows 88.6%
273 accuracy (see figure 3)[37].

274 *Task-based EEG*

275
276 A first important domain affected in AD is **encoding and memory**. Tautvydaite [38] shows that
277 demAD patients show neural deficits in novelty detection and encoding during both learning and
278 delayed memory recognition of pictures. Specifically, demAD patients show a decreased P200
279 response to new and repeated items, reflecting attention and perceptual processing, as well as an
280 increased P300 during delayed repetition, which might reflect difficulties differentiating new from
281 familiar stimuli. Similarly, in a passive picture recognition task of Stothart [39], demAD patients
282 showed a decreased neural response to familiar pictures. Early differences in visual short term memory
283 have also been found by Pietto[40] showing a reduced N1, P2 and P3 in prodFAD. Several studies
284 including asymptomatic carriers of an AD causative genetic mutation, explored the potential of task-
285 based EEG for early detection, highlighting early neural functional alterations without corresponding
286 behavioral impairments. Golob [41] observed that presymptomatic carriers of the PSEN1 or APP
287 mutation (*mean age* = 33.9), show discriminable neural alterations during an auditory target detection
288 task. These alterations included decreased slow wave amplitudes, increased P200 amplitude, and
289 delayed N100, N200, P200 and P300 latencies. Comparison of latencies across the ERP components
290 showed that the latencies in the asymptomatic carriers were around 10% longer than the noncarrier
291 group. Nontarget P200 latency emerged as a potent discriminator, successfully identifying 87% of the
292 presymptomatic carriers. Quiroz [42] observed that during a recognition memory task,
293 presymptomatic PSEN1 carriers showed lower frontal ERP positivity alongside an increased occipital
294 positivity, with 72.7% sensitivity and 81.8% specificity discrimination. Despite these neural
295 differences, both groups performed equally well on the task. Control subjects during recognition
296 memory, exhibited activation patterns reliably associated with frontally mediated processes
297 distinguishing between studied and unstudied visual items. PSEN1 carriers on the other hand, showed
298 increased brain activity in occipital regions associated with visual perceptual processing. Ochoa [43]
299 demonstrated a higher connectivity during the encoding condition of the same recognition memory
300 paradigm in PSEN1 presymptomatic carriers compared to non-carriers. Connectivity in the occipito-
301 parietal region during the same memory encoding condition within the 500-600ms time window is
302 able to differentiate between presymptomatic and non-carriers with 67 % sensitivity and 80 %
303 specificity [44]. P300 latency during an auditory oddball paradigm correlates with CSF levels of p-
304 tau181, p-tau199 and ptau231 across demAD, prodAD and HC, while N200 latency negatively
305 correlates with A β 42 [45]. Recent studies in preAD using a working memory paradigm point towards
306 reduced α event-related desynchronization (ERD) and altered α spectral entropy, suggesting
307 compensatory hyperactivity during low load and insufficient cognitive resources with increasing work
308 load [46, 47]. In the γ band, low working load induces a higher low γ in preAD, while decreases in γ
309 are observed during high load [48].

311

312 In the **language domain**, sources of ERPs during a semantic-matching task reveal distinct
 313 topographical patterns in presymptomatic carriers versus non-carriers, although their behavioral
 314 responses and N400 amplitudes remain similar [49]. Specifically, presymptomatic carriers show a
 315 notable decrease in N400 generator strength within the right inferior-temporal and medial cingulate
 316 areas, and an increase within the left hippocampus and parahippocampus compared to non-carriers.
 317 The observed shift in N400 distribution mirrored that seen in symptomatic carriers, albeit with a less
 318 pronounced reduction in generator strength.

Study	Study population	EEG acquisition	AUC	Sen	Spe	Acc
Cao, 2022	demAD	rsEEG				0.86
Durongbhan, 2019	demAD	rsEEG		0.93	0.89	0.90
Maturana-Candelas, 2019	demAD	rsEEG		0.88	0.52	0.79
Zhao, 2019	demAD	rsEEG				0.91
Babiloni, 2017	prodAD	rsEEG	0.79	0.71	0.75	0.73
Kim, 2021	preAD			0.86	0.89	0.89
	prodAD			0.83	0.86	0.85
Arakaki, 2022	preAD	tbEEG	0.73			
Suarez-Revelo, 2016	AcrFAD	tbEEG		0.67	0.80	
	prodFAD			0.83	0.67	
Quiroz, 2011	Acr	tbEEG		0.73	0.82	
Rodriguez, 2014	Acr	rsEEG	0.90			
	FAD		0.99			
Golob, 2009	FAD	tbEEG				0.87

319 **Figure 3.** AUROC values in AD studies. If multiple values were provided, only the highest value was reported. Studies were
 320 organized according to subpopulation. AD=Alzheimer’s Disease, prodemAD= prodromal AD, preAD= preclinical AD, Acr =
 321 Asymptomatic carriers, prodFAD= prodromal Familial AD, FAD= Familial AD, rs-EEG= resting-state EEG, tbEEG= task-
 322 based EEG, AUC= Area under the curve, Sen= sensitivity, Spe= specificity, Acc= accuracy

324 **Potential for FTD diagnosis**

325 *rsEEG*

326 Spectral analysis in FTD shows a consistent slowing of the frequency spectrum. While studies agree
 327 on a slowing in α frequencies, there is some discrepancy regarding the changes in the β band, with
 328 some indicating a decrease and others suggesting an increase [9, 50]. In the study of Herzog [51],
 329 hypoconnectivity in the δ band between frontal, temporal, parietal and posterior areas emerged as the
 330 most relevant EEG feature, showing excellent AUC values in the discrimination of bvFTD from HC
 331 (figure 4). One study found right frontotemporal hypoconnectivity in bvFTD, which correlated with
 332 deficits in a naturalistic social text task [52].

333 Microstates were investigated in two studies. One study found that microstate duration C was
 334 decreased in FTD and that the sequence of activation from C to D was reversed [53]. Another study
 335 found that microstates vary with disease progression, showing an initial increase in microstate D, and

336 a decrease as disease duration prolongs in CHMP2B-FTD [54]. These conflicting results could be
 337 explained by the different stages and variants of FTD. More specifically, microstate C is linked to the
 338 insular-cingulate network, linked to changes in personality typical of bvFTD. In contrast, CHMP2B-
 339 FTD presents with early impairments in executive functioning, with behavioural symptoms occurring
 340 at a later stage of the disease [54]. Microstate D has previously been linked to the fronto-parietal
 341 network, the initial increase followed by a decline in microstate D activation may be interpreted as a
 342 temporary compensatory mechanism. Studies using ML classification achieve encouraging AUC
 343 values between 0.78-0.96 for bvFTD and 0.78 for PPA versus HC (see figure 4). Moral-Rubio [55]
 344 also discriminated between nfvPPA, svPPA and IPPA variants, with 58% accuracy.

345
 346 *Task based EEG*

347 Only one out of 10 studies included a task-based Go/No go paradigm, showing differences in θ and δ
 348 modulation related to impaired inhibition [56].

Study	Study population	EEG acquisition	AUC/ROC	Sen	Spe	Acc
Herzog, 2022	bvFTD	rsEEG	0.96	0.96	0.82	0.92
Moguilner, 2022	bvFTD	rsEEG	0.78			
Lindau, 2003	FTD	rsEEG				0.79
Nishida, 2011	FTD	rsEEG	0.69	0.55	0.84	
Moral-Rubio, 2021	PPA	rsEEG	0.78			

349
 350 **Figure 4.** AUROC values in FTD studies. If multiple values were provided, only the highest value was reported. Studies
 351 were organized according to subpopulation. bvFTD= behavioral variant Frontotemporal Dementia, FTD= Frontotemporal
 352 Dementia, PPA= Primary Progressive Aphasia, rsEEG=resting-state EEG, AUC= Area under the curve, Sen=sensitivity,
 353 Spe= specificity, Acc= accuracy

354
 355 *Potential DLB*

356 *rsEEG*

357 The most consistent finding in DLB compared to HC is slowing of the EEG pattern. More specifically,
 358 results show a leftward shift in mean dominant frequency (DF) from α range to pre- α or high- θ (6-7.5
 359 Hz), in anterior [57], occipital [58, 59], posterior [60], or widespread areas [61]. Similarly, increased
 360 power in low frequency bands [61, 62] and decreased power in high frequency bands [61], as well as
 361 decreased θ/α ratio [58], differences α/θ and α/δ ratio [60] are observed. Using the θ/α ratio, DLB
 362 patients can be discriminated from HC with 76.7% sensitivity, 61.7% specificity and 66.7% accuracy
 363 [63]. In DLB patients with visual hallucinations, parietal δ activity achieves 75% sensitivity, 85%
 364 specificity, 81% accuracy in discrimination from HC. Posterior α reactivity from EC to EO is reduced
 365 in DLB, suggesting altered neural vigilance in the occipital lobe, enabling discrimination of DLB with
 366 95.2% sensitivity [64].

367
 368 In terms of connectivity, DLB patients show consistent network disorganization. DLB was
 369 characterized by network randomization and reduced connectivity in the α and β band [59, 65, 66]
 370 combined with increased network complexity in the high- θ band [59]. Similarly, combining

371 connectivity strength of the β band with graph features of α band achieved an 76% accuracy in
 372 differentiating DLB from HC in the study of Mehraram [67]. In terms of dynamic connectivity, DLB
 373 patients show reduced α band information flow between posterior to anterior areas [68]. Functional
 374 source connectivity suggests cortical disconnection in DLB as both intra- and interhemispheric lagged
 375 linear connectivity (LCC) in the α range are reduced. Interhemispheric LCC in α range achieves good
 376 discrimination [69]. In the study of Kai [62], decreases in interhemispheric coherence (Icoh) and
 377 intrahemispheric coherence (Hcoh) were besides α also pronounced for δ , β and θ frequencies. In
 378 terms of large-scale resting state networks (RSN), connectivity decreases are found in the visual and
 379 sensorimotor network [65].

380
 381 Two studies on microstates found contrasting results. In the study of Schumacher [70] microstate
 382 duration of all microstates was increased with reductions in numbers of microstates per second in
 383 DLB. Lamos [71] found the opposite direction of changes in prodDLB, with increased occurrence of
 384 all microstates, and shorter mean duration and increased occurrence of microstate B, which is
 385 associated with the visual network.

386
 387 *Task-based EEG*
 388

389 Three studies included a task-based EEG paradigm. One study used an auditory oddball paradigm and
 390 found a reduced and delayed P300 amplitude, as well as a P300 latency gradient inversion in DLB
 391 [72]. A longer latency of the P300 was also found in a visual oddball task [73]. Interestingly, oddball
 392 tasks reveal differences in EEG oscillations reflecting typical DLB symptoms. More specifically, DLB
 393 patients show a decreased event-related δ synchronization combined with impaired α and β
 394 suppression during both visual and auditory oddball tasks, and decreased θ band activity in a visual
 395 task [73, 74]. From a clinical perspective, decreased event-related θ oscillations and decreased α
 396 suppression during a visual oddball task may serve as neurophysiological correlates of attention and
 397 visual dysfunction in DLB. Power in δ band was able to discriminate DLB from HC with good
 398 sensitivity and specificity [74].

Study	Study population	EEG acquisition	AUC/ROC	Sen	Spe	Acc
Babiloni, 2022	DLB	rsEEG	0.80	0.95	0.61	0.75
Babiloni, 2018a	DLB	rsEEG	0.78	0.84	0.65	0.74
Mehraram, 2021	DLB	rsEEG	0.82	0.59	1.00	0.76
Pascarelli, 2020	DLB VH+	rsEEG	0.85	0.75	0.85	0.81
	DLB MMSE+	rsEEG	0.70	0.77	0.62	0.67
Rosenblum, 2022	DLB	tbEEG	0.75	0.75	0.72	

399
 400
 401 **Figure 5.** AUROC values in DLB studies. If multiple values were provided, only the highest value was reported. Studies
 402 were alphabetically organized. DLB= Dementia with Lewy Bodies, DLB VH+= DLB with visual hallucinations, DLB
 403 MMSE+= DLB with pathological Mini Mental State Examination scores, rsEEG= resting-state EEG, tbEEG= task-based
 404 EEG, AUC= Area under the curve, Sen=sensitivity, Spe= specificity, Acc= accuracy.

405
 406
 407

408 *Potential for discrimination*

409 *AD versus DLB*

410 Studies comparing prodAD and prodDLB consistently find a more pronounced slowing in prodDLB
411 compared to prodAD [75–77]. To account for interindividual variability, individual α frequency peaks
412 (IAF, maximum power peak between 6-14Hz) and transition frequency between α and θ band (TF,
413 minimum power density between 3-8Hz) can be used. Reduced mean TF and mean IAF values are
414 consistent observations across DLB studies [63, 69, 70]. In the study of Babiloni [78] mean TF and
415 mean IAF were found to be lowered in both prodAD ($m_{IAF}=8.8\text{Hz}$, $m_{TF}=5.4$) and prodDLB compared
416 to HC ($m_{IAF}=9.4\text{Hz}$, $m_{TF}=96.3\text{Hz}$) with more pronounced reductions in prodDLB ($m_{IAF}=7.8\text{Hz}$, m_{TF}
417 $=4.7\text{Hz}$). In the discrimination of prodAD from prodDLB, sensitivity values for spectral metrics range
418 between 41 to 78.3%, while specificity values range between 66.7 to 97% (see figure 6) [76, 78]. The
419 leftward shift in the power spectrum in DLB was also confirmed in the study of Massa [75], where α/θ
420 ratio was found to be decreased in prodDLB compared to prodAD, and in the study of Schumacher
421 [76], where increases in θ/α ratio were correlated with more severe cases of prodDLB. In the study of
422 Schumacher [76], β power showed the highest AUC (0.71) in discriminating prodAD from prodDLB,
423 with 61% sensitivity and 81% specificity. Discrimination between DLB and AD with high β power as
424 the most important factor, shows good sensitivity and specificity (see figure 6) [68]. Babiloni [79]
425 found that inter- and intrahemispheric LCC values in the α band were reduced in both prodAD and
426 prodDLB compared to HC. While intra-hemispheric LCC α_2 was best to differentiate prodDLB from
427 HC, interhemispheric LCC global α_2 was best to differentiate prodAD from HC. However,
428 discrimination between prodAD and prodDLB remained low (AUC <0.7).

429 *AD versus FTD*

430 While both FTD and AD show progressive connectivity alterations compared to HC, profound
431 frequency- and location dependent differences can be found in network organization, which are linked
432 to the core areas of the diseases. Compared to bvFTD, demAD patients show lower connectivity in the
433 α and δ band in posterior regions and a widespread higher connectivity in the θ band [80]. bvFTD
434 patients showed an inverse pattern, with preserved posterior alpha connectivity, but lower θ activity in
435 posterior and frontal areas. The Minimum Spanning Tree (MST) analyses indicate that frontal
436 networks appear to be selectively involved in bvFTD, whereas in AD, global efficiency is reduced
437 [80]. In the study of Franciotti [81], the typical main hub in HC is lost in FTD at dementia onset and
438 replaced by frontal local hubs, while network organization is largely preserved in demAD. In the same
439 study, global clustering was able to distinguish between FTD (PPA and bvFTD) and demAD with
440 moderate sensitivity but high specificity (see figure 6). In the study of Bonanni [82], network
441 alterations predominantly targeted the frontal region in pFTD, while in prodAD, mutual information in
442 the left local anterior region discriminated prodFTD from prodAD with good sensitivity but low
443 specificity (see figure 6). Using the same metric, discrimination of pFTD from HC reached 89%
444 sensitivity and 90% specificity. For the discrimination of prodAD from HC, MI in the posterior
445 connections achieved high sensitivity (89-100%) and specificity (85-100%). Interestingly, these
446 effects were evident in the prodromal stages of the disease but diminished with progression, which is
447 suggestive of hyperconnectivity as a temporary compensatory mechanism to account for the effects of
448 neurodegeneration in the core areas of the specific disease.

Study	Study population	EEG acquisition	AUC/ROC	Sen	Spe	Acc
Babiloni, 2018b	prodAD vs prodDLB	rsEEG	0.72	0.78	0.67	0.73
Schumacher, 2020	prodAD vs prodDLB		0.71	0.61	0.81	
Dauwan, 2016b	DLB vs demAD	rsEEG		0.86	0.85	0.85
Bonanni, 2021	FTD (PPA&bvFTD) vs AD	rsEEG	0.71	0.89	0.44	
Franciotti, 2022	FTD(PPA&bvFTD) vs AD	rsEEG	0.80	0.67	1.00	

449
450

451 **Figure 6.** AUROC values in discriminative studies. If multiple values were provided, only the highest value was reported.
452 prodAD= prodromal Alzheimer’s Disease, prodDLB= prodromal Dementia with Lewy Bodies, prodFTD= prodromal
453 Frontotemporal Dementia, DLB= Dementia with Lewy Bodies, demAD= dementia due to Alzheimer’s Disease, PPA=
454 Primary Progressive Aphasia, bvFTD= behavioral variant Frontotemporal Dementia, rsEEG= resting-state EEG, tb-
455 EEG=task-based EEG, AUC= Area under the curve, Sen=sensitivity, Spe= specificity, Acc= accuracy.

456
457
458

Discussion

459 To the best of our knowledge, this is the first systematic review to evaluate the diagnostic utility of
460 EEG across AD, FTD, DLB as well as their preclinical and prodromal stages. The findings reveal
461 promising AUC values across diseases and disease stages, which suggest that EEG holds significant
462 diagnostic utility in AD, FTD and DLB. This, in combination with the advantages of EEG such as
463 cost-effectiveness and non-invasiveness, could make EEG a valuable tool for the detection of
464 neurodegenerative diseases.

Potential for diagnosis of AD, FTD and DLB at the dementia stage

466 In AD, the leftward shift towards lower frequencies is a well-established finding, characterized by
467 reductions in spectral and connectivity metrics in higher frequencies α and β , while increases in these
468 metrics are found in δ and θ bands [21–23, 25–27]. Discrimination of AD based on frequency data is
469 promising with excellent sensitivity values ranging from 88 to 93%, albeit lower specificity between
470 52-89% (see figure 3). In DLB, similar patterns of slowing arise as the most consistent findings [57–
471 63, 69, 70]. Discrimination of DLB from HC using spectral metrics ranges between 75-95%
472 sensitivity, 61-85% specificity and 66.7-81% accuracy (see figure 5). Similarly, reduced connectivity
473 is found, especially within the α range [59, 62, 65–69]. Depending on the analysis, discrimination
474 based on connectivity measures is lower with sensitivity values of 59-84%, specificity of 65-100%,
475 and accuracy of 74-76% (see figure 5). Overall, the high sensitivity values suggest that frequency data
476 holds promise as a screening tool in both AD and DLB.

477
478 Preliminary studies on FTD (bvFTD and PPA) have reported varying AUC values (ranging between
479 0.69-0.96, figure 4), however, due to the heterogeneity of the FTD spectrum, the variation in analysis
480 techniques and the limited amount of studies, direct comparisons of AUC values are challenging. In
481 bvFTD, connectivity analysis achieves the most encouraging AUC values [51, 83]. A different
482 promising avenue could be microstate analysis, with alterations in microstate C and D, varying

483 according to the subtype and stage of the disease [53, 54]. However, without ROC analysis to validate
484 its effectiveness, the value of microstate analysis remains uncertain.

485

486 *Potential for early diagnosis*

487 In prodAD, slowing of the frequency spectrum is the most consistent observation with slowing
488 patterns similar to those observed in AD, with the most prominent and consistent reductions in alpha,
489 TF and IAF [17, 18, 20, 21, 23]. Discrimination of prodAD from MCI without AD biomarkers and HC
490 achieves moderate sensitivity and specificity values (see figure 3). One explanation might be that
491 alterations in spectral metrics start before the start of preclinical AD and develop differently across
492 individuals. Recent studies have reported interindividual variability in EEG metrics, depending on the
493 degree of amyloid burden and neurodegeneration [35] as well as the interaction with other factors
494 modulating brain activity such as age [19] and education levels [18, 84].

495

496 Research on early stages of FTD is limited, with only one study including presymptomatic carriers of
497 a FTD causative mutation, suggesting progressive alterations in microstates [54]. More precise, the
498 upregulation of microstate D activity in the early stages of the disease might be a temporal
499 compensatory mechanism. However, as the disease progresses and the brain's capacity to maintain this
500 compensation diminishes, microstate D activity decreases. Similarly, microstate alterations have been
501 suggested as a potential early marker for prodDLB, with alterations inverse to those in the dementia
502 stage of the disease, which again may be explained by early maladaptive mechanisms [71].

503

504

505 *Potential for differential diagnosis*

506 Another key issue is the differential diagnosis of neurodegenerative diseases which is complicated due
507 to overlap in clinical symptoms and heterogeneity of the diseases. A leftward shift in the power
508 spectrum is a consistent finding in all three populations, AD [17–22], FTD [9, 50] and DLB [57–62],
509 raising questions regarding the specificity of this phenomenon. Studies comparing prodAD and
510 prodDLB consistently find a more pronounced slowing in prodDLB, with good specificity values
511 (66.7-97%) for the alpha band but low sensitivity (41-78.3%). In the study of Schumacher (2020),
512 sensitivity values range between 23 and 61%, while specificity were higher between 81 and 89% for
513 different frequency bands. The high specificity across studies suggests that a significant shift in the
514 power spectrum is more likely to be indicative for prodDLB rather than prodAD. However, the low
515 sensitivity values, indicate that in cases with less disturbed EEG patterns, differentiating between the
516 two becomes increasingly difficult. As the disease progresses, discrimination between DLB and AD
517 shows better sensitivity (86%) and specificity (85%) [85]. Interestingly, alterations link to the key
518 areas of the diseases. In DLB, the slowing of EEG frequencies is more pronounced in posterior regions
519 [58–60]. In FTD, reductions in alpha band are pronounced in frontal areas, which corresponds to
520 anatomical and metabolic changes in these areas in FTD patients [50]. Connectivity studies provide
521 similar evidence. In FTD, network alterations predominantly target frontal regions [80–82], aligning
522 with the progressive frontal disconnection characteristic of the disease. In contrast, more widespread
523 or posterior alterations seem to be more suggestive of AD [80, 82]. In DLB, functional connectivity is
524 reduced in the visual and sensorimotor network [65] and information flow is reduced between posterior
525 to anterior regions [68].

526

527

528 *Potential of task-based versus resting state EEG*

529 While resting-state EEG measures spontaneous activity, task-based EEG captures the complex
530 dynamics underlying cognitive processes that are affected in neurodegenerative diseases, thereby
531 increasing interpretability. Task-based paradigms offer unique insights into the neural substrates of
532 AD-related symptoms, showing alterations in auditory and visual target detection and memory
533 recognition [38, 39, 41, 45]. Notably, task-based EEG has been studied extensively in the earliest
534 stages of AD (figure 1c). Task-based EEG highlights early, subtle changes in neural processing of

535 memory and language preceding deficits in performance in presymptomatic FAD carriers [41–43, 49].
536 More specifically, early alterations are present in well-known ERP components N100, N200, P200 and
537 P300 that are also found in prodFAD [40] and demAD [38]. Sensitivity values of task-based
538 paradigms identifying carriers from noncarriers range from 67–72.7% and 80–81.8% specificity (see
539 figure 3), which is comparable to symptomatic stages. The ability to detect early neural changes before
540 the onset of symptoms is perhaps one of the most promising findings, as it could revolutionize how we
541 approach AD.

542 Three studies in DLB employed task-based EEG, offering insights into the neural substrates of
543 cognitive deficits in DLB. During oddball tasks, reduced and delayed P300 amplitudes are found,
544 relating to deficits in attention and executive functioning [72, 73]. Furthermore, DLB patients show a
545 decreased event-related δ and θ synchronization combined with impaired α and β suppression, which
546 may serve as a neurophysiological correlate of visual and attentional dysfunction in DLB showing
547 promising sensitivity and specificity values [73, 74]. We found no task-based studies discriminating
548 between neurodegenerative diseases, despite evidence of alterations in task-based analyses, such as
549 delayed P300 effects which have been reported in both AD [41, 45] and DLB [72, 73].

550
551

Limitations

552 The available academic literature on the diagnostic utility of EEG markers between AD, FTD and
553 DLB shows notable gaps. First, there is an underrepresentation of studies including FTD patients,
554 which limits the ability to make statements about the most promising avenue in diagnosing FTD and
555 discriminating FTD from other neurodegenerative diseases. Furthermore, there is a scarcity of studies
556 comparing across neurodegenerative diseases, which limits the ability to make statements on the
557 specificity of some markers.
558

559 The established heterogeneity within the AD, FTD and DLB population is thought to play a major role
560 in the sometimes conflicting outcomes of prior research. As is shown in our review, not all disease
561 stages within these neurodegenerative diseases are equally represented. Studies including multiple
562 disease stages have shown differences in the EEG markers with progression of the disease. As not all
563 studies describe disease duration, conflicting results might be partially explained by different disease
564 stages. On the other hand, it is clear that other factors which are hard to model in their entirety impact
565 disease presentation and severity besides disease duration. In our bias assessment, we paid special
566 attention to the matching of confounding factors such as age and education that were studied in
567 multiple studies. Education has been shown to influence alpha activity, serving a neuroprotective and
568 compensatory role in AD [84]. A parallel pattern can be found between brain activity and cognitive
569 reserve (CR), the brain's resilience to neuropathology and neurodegeneration in prodAD [18]. In
570 studies using a working memory paradigm, CR translated into better neural efficiency, evidenced by
571 increased α ERD and decreased α SpecEn during high working load [47]. Taken together, these
572 findings suggest both a compensatory mechanism in mitigating consequences of brain slowing in AD.
573 Finally, the impact of neuropathological co-pathology remains largely uncharted territory.
574

575 In terms of methodology, the variety in markers of interest, methods and analysis along with a scarcity
576 in reporting of AUROC values, severely limits the possibility for meta-analysis and statements about
577 the most promising marker. Recent work shows promise in harmonizing EEG data across centers
578 using novel post-processing methods [86].
579

580 The interpretation of EEG markers and their link to clinical symptoms remains largely unclear.
581 Research exploring the correlation between neural mechanisms and clinical symptoms is particularly
582 valuable in increasing the interpretability of neural alterations. For example, spectral and connectivity
583 measures may clarify the association between DLB pathology and clinical symptoms. Multiple authors
584 have proposed that a cholinergic deficit underlies α band network alterations [59, 65, 66]. Since α
585 oscillations are involved in thalamo- and corticocortical communication crucial for cognitive
586 processing, it is speculated that α band network alterations may connect cholinergic deficits to key

587 clinical symptoms in attention, perception and memory [59, 65, 66]. Finally, task-based EEG shows a
588 clear advantage to mechanistically study specific cognitive processes at the earliest disease stages,
589 when neural changes are still relatively limited.

590

591

Conclusions and future directions

592 In conclusion, EEG markers show promising AUC values for detecting AD, FTD and DLB. For the
593 detection of early neural changes, task-based EEG markers are particularly valuable in identifying the
594 earliest stages of AD, revealing neurophysiological changes before clinical symptoms become
595 apparent. While promising sensitivity values are reported in the diagnosis of AD, FTD and DLB, the
596 specificity of these biomarkers ask for further research. The most established marker, slowing of the
597 EEG spectrum, seems to be rather a marker of neurodegeneration than specific to a certain disease.
598 However, frequency-dependent connectivity aids interpretation, illustrating disease-specific alterations
599 corresponding with the core regions and symptoms affected by each disease. Exploration of both
600 spectral metrics and microstates could be beneficial, especially with the intent towards discrimination
601 from early stages of AD, which is important for clinical application.

602

603 To reduce heterogeneity in sample sizes, future studies should strive for clear descriptions of disease
604 duration and demographic factors such as age and education levels. There is a growing body of
605 evidence illustrating the influence of interindividual variability on the onset and progression of AD.
606 Given the complex nature of disease progression, the modulatory and compensatory mechanisms of
607 these diseases should be further explored. Furthermore, future research must validate previous findings
608 in multicentric studies combining disease populations. Equally important will be the standardization of
609 research protocols, including up-to date consensus criteria, and reporting of methods allowing
610 replication and enhancing generalizability and interpretability.

611

612 In conclusion, the use of EEG shows promise in diagnostic accuracy and differential diagnosis and
613 shows advantages in non-invasiveness, availability and cost-effectiveness. With further research, the
614 search for the most optimal EEG marker could revolutionize the diagnosis of AD, FTD and DLB,
615 establishing an early and accurate detection of neurodegeneration.

616

617

618

619

620

621

622

623

624

625

626

627

Acknowledgements

628 SVM, TVDB, DC, PC and RB are members of the European Reference Network for Rare Neurological Diseases - Project ID
629 No 101085584.

630

631

List of abbreviations

Ab42	Amyloid plasma
AEC	amplitude envelope correlation
AEC-c	AEC with leakage correction
AMI	Auto mutual information
ApEn	Approximate entropy
BispEn	bispectrum cubic entropy
BispMF	bispectrum median frequency
BispRP	Bispectrum relative power
CC	Clustering Coefficient
Coh	Mean global coherence
Cross-ApEn	Cross-Approximate Entropy
CSA	Compressed spectral arrays
CSD	Current Source Density
D2	Mahalanobis distance
DAR	δ to α ratio
DF	Dominant frequency
DFV	Dominant frequency variance
DRC	Dynamic Range of Connectivity
DT	Decision Tree's
DTF	directed transfer function
DWT	Discrete Wavelet Transform
EA	EEG abnormalities
ERD	Event related desynchronization
ERO	Event Related Oscillations
ERS	Event Related synchronisation
FC	Functional Connectivity
FP	Frequency Prevalence
GEV	global explained variance
GFP	Global Field Power
GMFP	Global Mean Field Power
GSA	Gready search algorithm
GTA	Graph Theory Analysis
HC	Hjorth Complexity
HHT	Hilbert Huant transform
HOFC	Higher order functional connectivity
IAC	instantaneous amplitude correlation
iCoh	Imaginary coherence
ITPC	inter-trial phase clustering
kNN	k-nearest neighbour
LDA	Linear discriminant analysis
LLC	Lagged linear coherence
LOOcv	Leave one out cross validation
LOSO	Leave one subject out (cross-validation)
LR	Logistic Regression
LZC	Lempel-Ziv Complexity
MF	Median frequency
MI	Mutual information

MSCOH	magnitude squared coherence	633
MSE	Multiscale Sample Entropy	634
MSSE	Multiscale SpecEn	
MST	Minimum Spanning Tree	
MWC	Morlet wavelet convolution	
NB	Naive Bayes	
NCA	neighbourhood component analysis	
NDTF	non-normalized directed transfer function	
PCA	Principal Component Analysis	
PL	Path Length	
PLI	Phase Lag index	
PLV	Phase Locking Value	
PSA	Power Spectrum analysis	
PSD	Power Spectrum Density	
PSI	Phase synchronization index	
PTE	Phase Transfer Entropy	
QDA	Quadratic Discriminant Analysis	
RCG	Revised Circular Graph	
RF	Random Forest	
RMS	Root mean square	
rMSSE	refined MSSE	
RNN	recurrent neural network	
RP	Relative Power	
RSN	Resting State Network	
SampEn	Sample Entropy	
SE	Shannon Entropy	
SMR	Stepwise multilinear regression	
SNR	Signal to noise ratio	
SP	Spectral power	
SpecEn	Spectral Entropy	
SPR	Statistical Pattern Recognition	
SR	Spectral Ratio	
SVM	Support Vector Machine	
TAR	Theta to alpha ratio	
TAS	temporal activation sequence (TAS)	
TBR	Theta to beta ratio	
TF	Transition Frequency	
wPLI	weighted PLI	
wSMI	weighted symbolic mutual information	
WT	Wavelet Transform	

635

636

References

- 637 1. Nichols E, Steinmetz JD, Vollset SE, et al (2022) Estimation of the global prevalence of dementia
638 in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study
639 2019. *Lancet Public Health* 7:e105–e125. [https://doi.org/10.1016/s2468-2667\(21\)00249-8](https://doi.org/10.1016/s2468-2667(21)00249-8)
- 640 2. Galimberti D, Scarpini E (2011) Disease-modifying treatments for Alzheimer’s disease. *Ther Adv*
641 *Neurol Disord* 4:203–216. <https://doi.org/10.1177/1756285611404470>
- 642 3. Dubois B, Hampel H, Feldman HH, et al (2016) Preclinical Alzheimer’s disease: Definition,
643 natural history, and diagnostic criteria. *Alzheimers Dement* 12:292–323.
644 <https://doi.org/10.1016/j.jalz.2016.02.002>
- 645 4. Cassani R, Estarellas M, San-Martin R, et al (2018) Systematic Review on Resting-State EEG for
646 Alzheimer’s Disease Diagnosis and Progression Assessment. *Dis Markers* 2018:1–26.
647 <https://doi.org/10.1155/2018/5174815>
- 648 5. Paitel ER, Samii MR, Nielson KA (2021) A systematic review of cognitive event-related
649 potentials in mild cognitive impairment and Alzheimer’s disease. *Behav Brain Res* 396:112904.
650 <https://doi.org/10.1016/j.bbr.2020.112904>
- 651 6. McKeith IG, Boeve BF, Dickson DW, et al (2017) Diagnosis and management of dementia with
652 Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* 89:88–100.
653 <https://doi.org/10.1212/wnl.0000000000004058>
- 654 7. Law ZK, Todd C, Mehraram R, et al (2020) The Role of EEG in the Diagnosis, Prognosis and
655 Clinical Correlations of Dementia with Lewy Bodies—A Systematic Review. *Diagnostics* 10:616.
656 <https://doi.org/10.3390/diagnostics10090616>
- 657 8. Cromarty RA, Elder GJ, Graziadio S, et al (2016) Neurophysiological biomarkers for Lewy body
658 dementias. *Clin Neurophysiol* 127:349–359. <https://doi.org/10.1016/j.clinph.2015.06.020>
- 659 9. Lindau M, Jelic V, Johansson S-E, et al (2003) Quantitative EEG Abnormalities and Cognitive
660 Dysfunctions in Frontotemporal Dementia and Alzheimer’s Disease. *Dement Geriatr Cogn Disord*
661 15:106–114. <https://doi.org/10.1159/000067973>
- 662 10. Caso F, Cursi M, Magnani G, et al (2012) Quantitative EEG and LORETA: valuable tools in
663 discerning FTD from AD? *Neurobiol Aging* 33:2343–2356.
664 <https://doi.org/10.1016/j.neurobiolaging.2011.12.011>
- 665 11. Dubois B, Feldman HH, Jacova C, et al (2007) Research criteria for the diagnosis of Alzheimer’s
666 disease: revising the NINCDS–ADRDA criteria. *Lancet Neurol* 6:734–746.
667 [https://doi.org/10.1016/s1474-4422\(07\)70178-3](https://doi.org/10.1016/s1474-4422(07)70178-3)
- 668 12. Dubois B, Feldman HH, Jacova C, et al (2014) Advancing research diagnostic criteria for
669 Alzheimer’s disease: the IWG-2 criteria. *Lancet Neurol* 13:614–629.
670 [https://doi.org/10.1016/s1474-4422\(14\)70090-0](https://doi.org/10.1016/s1474-4422(14)70090-0)
- 671 13. Rascovsky K, Hodges JR, Knopman D, et al (2011) Sensitivity of revised diagnostic criteria for
672 the behavioural variant of frontotemporal dementia. *Brain* 134:2456–2477.
673 <https://doi.org/10.1093/brain/awr179>

- 674 14. Gorno-Tempini ML, Hillis AE, Weintraub S, et al (2011) Classification of primary progressive
675 aphasia and its variants. *Neurology* 76:1006–1014.
676 <https://doi.org/10.1212/wnl.0b013e31821103e6>
- 677 15. McKeith IG, Dickson DW, Lowe J, et al (2005) Diagnosis and management of dementia with
678 Lewy bodies: Third report of the DLB consortium. *Neurology* 65:1863–1872.
679 <https://doi.org/10.1212/01.wnl.0000187889.17253.b1>
- 680 16. Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated
681 guideline for reporting systematic reviews. *BMJ* n71. <https://doi.org/10.1136/bmj.n71>
- 682 17. Babiloni C, Del Percio C, Lizio R, et al (2017) Abnormalities of Cortical Neural Synchronization
683 Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s
684 Diseases: An EEG Study. *J Alzheimers Dis* 59:339–358. <https://doi.org/10.3233/jad-160883>
- 685 18. Babiloni C, Ferri R, Noce G, et al (2021) Abnormalities of Cortical Sources of Resting State
686 Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively
687 Unimpaired Seniors and Patients with Alzheimer’s Disease and Amnesic Mild Cognitive
688 Impairment. *Cereb Cortex* 31:2220–2237. <https://doi.org/10.1093/cercor/bhaa356>
- 689 19. Babiloni C, Ferri R, Noce G, et al (2021) Resting State Alpha Electroencephalographic Rhythms
690 Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with
691 Alzheimer’s Disease and Amnesic Mild Cognitive Impairment. *J Alzheimers Dis* 82:1085–1114.
692 <https://doi.org/10.3233/jad-201271>
- 693 20. Polverino P, Ajčević M, Catalan M, et al (2022) Brain oscillatory patterns in mild cognitive
694 impairment due to Alzheimer’s and Parkinson’s disease: An exploratory high-density EEG study.
695 *Clin Neurophysiol* 138:1–8. <https://doi.org/10.1016/j.clinph.2022.01.136>
- 696 21. Cecchetti G, Agosta F, Basaia S, et al (2021) Resting-state electroencephalographic biomarkers of
697 Alzheimer’s disease. *NeuroImage Clin* 31:102711. <https://doi.org/10.1016/j.nicl.2021.102711>
- 698 22. Zhang H, Geng X, Wang Y, et al (2021) The Significance of EEG Alpha Oscillation Spectral
699 Power and Beta Oscillation Phase Synchronization for Diagnosing Probable Alzheimer Disease.
700 *Front Aging Neurosci* 13:. <https://doi.org/10.3389/fnagi.2021.631587>
- 701 23. Smailovic U, Koenig T, Kåreholt I, et al (2018) Quantitative EEG power and synchronization
702 correlate with Alzheimer’s disease CSF biomarkers. *Neurobiol Aging* 63:88–95.
703 <https://doi.org/10.1016/j.neurobiolaging.2017.11.005>
- 704 24. Rodriguez R, Lopera F, Alvarez A, et al (2014) Spectral Analysis of EEG in Familial Alzheimer’s
705 Disease with E280A Presenilin-1 Mutation Gene. *Int J Alzheimers Dis* 2014:1–10.
706 <https://doi.org/10.1155/2014/180741>
- 707 25. Maturana-Candelas A, Gómez C, Poza J, et al (2020) Inter-band Bispectral Analysis of EEG
708 Background Activity to Characterize Alzheimer’s Disease Continuum. *Front Comput Neurosci*
709 14:. <https://doi.org/10.3389/fncom.2020.00070>
- 710 26. Briels CT, Schoonhoven DN, Stam CJ, et al (2020) Reproducibility of EEG functional
711 connectivity in Alzheimer’s disease. *Alzheimers Res Ther* 12:. <https://doi.org/10.1186/s13195-020-00632-3>
- 712
- 713 27. Revilla-Vallejo M, Poza J, Gomez-Pilar J, et al (2021) Exploring the Alterations in the
714 Distribution of Neural Network Weights in Dementia Due to Alzheimer’s Disease. *Entropy*
715 23:500. <https://doi.org/10.3390/e23050500>

- 716 28. Lehmann D, Ozaki H, Pal I (1987) EEG alpha map series: brain micro-states by space-oriented
717 adaptive segmentation. *Electroencephalogr Clin Neurophysiol* 67:271–288.
718 [https://doi.org/10.1016/0013-4694\(87\)90025-3](https://doi.org/10.1016/0013-4694(87)90025-3)
- 719 29. Lian H, Li Y, Li Y (2021) Altered EEG microstate dynamics in mild cognitive impairment and
720 Alzheimer’s disease. *Clin Neurophysiol* 132:2861–2869.
721 <https://doi.org/10.1016/j.clinph.2021.08.015>
- 722 30. Smailovic U, Koenig T, Laukka EJ, et al (2019) EEG time signature in Alzheimer’s disease:
723 Functional brain networks falling apart. *NeuroImage Clin* 24:102046.
724 <https://doi.org/10.1016/j.nicl.2019.102046>
- 725 31. Perez-Valero E, Lopez-Gordo MÁ, Gutiérrez CM, et al (2022) A self-driven approach for multi-
726 class discrimination in Alzheimer’s disease based on wearable EEG. *Comput Methods Programs*
727 *Biomed* 220:106841. <https://doi.org/10.1016/j.cmpb.2022.106841>
- 728 32. Perez-Valero E, Morillas C, Lopez-Gordo MA, et al (2022) An Automated Approach for the
729 Detection of Alzheimer’s Disease From Resting State Electroencephalography. *Front*
730 *Neuroinformatics* 16:. <https://doi.org/10.3389/fninf.2022.924547>
- 731 33. Durongbhan P, Zhao Y, Chen L, et al (2019) A Dementia Classification Framework Using
732 Frequency and Time-Frequency Features Based on EEG Signals. *IEEE Trans Neural Syst Rehabil*
733 *Eng* 27:826–835. <https://doi.org/10.1109/tnsre.2019.2909100>
- 734 34. Zhao Y, Zhao Y, Durongbhan P, et al (2020) Imaging of Nonlinear and Dynamic Functional Brain
735 Connectivity Based on EEG Recordings With the Application on the Diagnosis of Alzheimer’s
736 Disease. *IEEE Trans Med Imaging* 39:1571–1581. <https://doi.org/10.1109/tmi.2019.2953584>
- 737 35. Gaubert S, Raimondo F, Houot M, et al (2019) EEG evidence of compensatory mechanisms in
738 preclinical Alzheimer’s disease. *Brain* 142:2096–2112. <https://doi.org/10.1093/brain/awz150>
- 739 36. Shim Y, Yang DW, Ho S, et al (2022) Electroencephalography for Early Detection of
740 Alzheimer’s Disease in Subjective Cognitive Decline. *Dement Neurocognitive Disord* 21:126.
741 <https://doi.org/10.12779/dnd.2022.21.4.126>
- 742 37. Kim NH, Yang DW, Choi SH, Kang SW (2021) Machine Learning to Predict Brain Amyloid
743 Pathology in Pre-dementia Alzheimer’s Disease Using QEEG Features and Genetic Algorithm
744 Heuristic. *Front Comput Neurosci* 15:. <https://doi.org/10.3389/fncom.2021.755499>
- 745 38. Tautvydaitė D, Adam-Darqué A, Andryszak P, et al (2022) Deficient Novelty Detection and
746 Encoding in Early Alzheimer’s Disease: An ERP Study. *Brain Topogr* 35:667–679.
747 <https://doi.org/10.1007/s10548-022-00908-x>
- 748 39. Stothart G, Smith LJ, Milton A, Coulthard E (2021) A passive and objective measure of
749 recognition memory in Alzheimer’s disease using Fastball memory assessment. *Brain* 144:2812–
750 2825. <https://doi.org/10.1093/brain/awab154>
- 751 40. Pietto M, Parra MA, Trujillo N, et al (2016) Behavioral and Electrophysiological Correlates of
752 Memory Binding Deficits in Patients at Different Risk Levels for Alzheimer’s Disease. *J*
753 *Alzheimers Dis* 53:1325–1340. <https://doi.org/10.3233/jad-160056>
- 754 41. Golob EJ, Ringman JM, Irimajiri R, et al (2009) Cortical event-related potentials in preclinical
755 familial Alzheimer disease. *Neurology* 73:1649–1655.
756 <https://doi.org/10.1212/wnl.0b013e3181c1de77>

- 757 42. Quiroz YT, Ally BA, Celone K, et al (2011) Event-related potential markers of brain changes in
758 preclinical familial Alzheimer disease. *Neurology* 77:469–475.
759 <https://doi.org/10.1212/wnl.0b013e318227b1b0>
- 760 43. Ochoa JF, Alonso JF, Duque JE, et al (2016) Successful Object Encoding Induces Increased
761 Directed Connectivity in Presymptomatic Early-Onset Alzheimer’s Disease. *J Alzheimers Dis*
762 55:1195–1205. <https://doi.org/10.3233/jad-160803>
- 763 44. Suárez Revelo JX, Ochoa Gomez JF, Duque Grajales JE, Tobón Quintero CA (2016) Biomarkers
764 identification in Alzheimer’s disease using effective connectivity analysis from
765 electroencephalography recordings. *Ing E Investig* 36:50.
766 <https://doi.org/10.15446/ing.investig.v36n3.54037>
- 767 45. Leko MB, Skorić MK, Klepac N, et al (2018) Event-related Potentials Improve the Efficiency of
768 Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease. *Curr*
769 *Alzheimer Res* 15:1244–1260. <https://doi.org/10.2174/1567205015666180911151116>
- 770 46. Arakaki X, Lee R, King KS, et al (2019) Alpha desynchronization during simple working memory
771 unmask pathological aging in cognitively healthy individuals. *PLOS ONE* 14:e0208517.
772 <https://doi.org/10.1371/journal.pone.0208517>
- 773 47. Arakaki X, Hung S-M, Rochart R, et al (2022) Alpha desynchronization during Stroop test
774 unmask cognitively healthy individuals with abnormal CSF Amyloid/Tau. *Neurobiol Aging*
775 112:87–101. <https://doi.org/10.1016/j.neurobiolaging.2021.11.009>
- 776 48. Rochart R, Liu Q, Fonteh AN, et al (2020) Compromised Behavior and Gamma Power During
777 Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau. *Front*
778 *Aging Neurosci* 12:. <https://doi.org/10.3389/fnagi.2020.574214>
- 779 49. Bobes MA, García YF, Lopera F, et al (2010) ERP generator anomalies in presymptomatic
780 carriers of the Alzheimer’s disease E280A *PS-1* mutation. *Hum Brain Mapp* 31:247–265.
781 <https://doi.org/10.1002/hbm.20861>
- 782 50. Nishida K, Yoshimura M, Isotani T, et al (2011) Differences in quantitative EEG between
783 frontotemporal dementia and Alzheimer’s disease as revealed by LORETA. *Clin Neurophysiol*
784 122:1718–1725. <https://doi.org/10.1016/j.clinph.2011.02.011>
- 785 51. Herzog R, Rosas FE, Whelan R, et al (2022) Genuine high-order interactions in brain networks
786 and neurodegeneration. *Neurobiol Dis* 175:105918. <https://doi.org/10.1016/j.nbd.2022.105918>
- 787 52. Birba A, Fittipaldi S, Cediél Escobar JC, et al (2022) Multimodal neurocognitive markers of
788 naturalistic discourse typify diverse neurodegenerative diseases. *Cereb Cortex* 32:3377–3391.
789 <https://doi.org/10.1093/cercor/bhab421>
- 790 53. Nishida K, Morishima Y, Yoshimura M, et al (2013) EEG microstates associated with salience
791 and frontoparietal networks in frontotemporal dementia, schizophrenia and Alzheimer’s disease.
792 *Clin Neurophysiol* 124:1106–1114. <https://doi.org/10.1016/j.clinph.2013.01.005>
- 793 54. Musaeus CS, Pedersen JS, Kjær TW, et al (2021) Cortical Frontoparietal Network Dysfunction in
794 CHMP2B-Frontotemporal Dementia. *Front Aging Neurosci* 13:.
795 <https://doi.org/10.3389/fnagi.2021.714220>
- 796 55. Moral-Rubio C, Balugo P, Fraile-Pereda A, et al (2021) Application of Machine Learning to
797 Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. *Brain*
798 *Sci* 11:1262. <https://doi.org/10.3390/brainsci11101262>

- 799 56. Díaz-Rivera MN, Birba A, Fittipaldi S, et al (2022) Multidimensional inhibitory signatures of
800 sentential negation in behavioral variant frontotemporal dementia. *Cereb Cortex* 33:403–420.
801 <https://doi.org/10.1093/cercor/bhac074>
- 802 57. Franciotti R, Pilotto A, Moretti DV, et al (2020) Anterior EEG slowing in dementia with Lewy
803 bodies: a multicenter European cohort study. *Neurobiol Aging* 93:55–60.
804 <https://doi.org/10.1016/j.neurobiolaging.2020.04.023>
- 805 58. Jennings JL, Peraza LR, Baker M, et al (2022) Investigating the power of eyes open resting state
806 EEG for assisting in dementia diagnosis. *Alzheimers Res Ther* 14:.
807 <https://doi.org/10.1186/s13195-022-01046-z>
- 808 59. Peraza LR, Cromarty R, Kobeleva X, et al (2018) Electroencephalographic derived network
809 differences in Lewy body dementia compared to Alzheimer’s disease patients. *Sci Rep* 8:.
810 <https://doi.org/10.1038/s41598-018-22984-5>
- 811 60. Bonanni L, Thomas A, Tiraboschi P, et al (2008) EEG comparisons in early Alzheimer’s disease,
812 dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-
813 up. *Brain* 131:690–705. <https://doi.org/10.1093/brain/awm322>
- 814 61. Stylianou M, Murphy N, Peraza LR, et al (2018) Quantitative electroencephalography as a marker
815 of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. *Clin*
816 *Neurophysiol* 129:1209–1220. <https://doi.org/10.1016/j.clinph.2018.03.013>
- 817 62. Kai T, Asai Y, Sakuma K, et al (2005) Quantitative electroencephalogram analysis in dementia
818 with Lewy bodies and Alzheimer’s disease. *J Neurol Sci* 237:89–95.
819 <https://doi.org/10.1016/j.jns.2005.05.017>
- 820 63. Pascarelli MT, Del Percio C, De Pandis MF, et al (2020) Abnormalities of resting-state EEG in
821 patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms.
822 *Clin Neurophysiol* 131:2716–2731. <https://doi.org/10.1016/j.clinph.2020.09.004>
- 823 64. Babiloni C, Lorenzo I, Lizio R, et al (2022) Reactivity of posterior cortical
824 electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and
825 patients with dementia due to Alzheimer’s and Lewy body diseases. *Neurobiol Aging* 115:88–
826 108. <https://doi.org/10.1016/j.neurobiolaging.2022.04.001>
- 827 65. Aoki Y, Kazui H, Pascal-Marqui RD, et al (2019) EEG Resting-State Networks in Dementia with
828 Lewy Bodies Associated with Clinical Symptoms. *Neuropsychobiology* 77:206–218.
829 <https://doi.org/10.1159/000495620>
- 830 66. Van Dellen E, De Waal H, Van Der Flier WM, et al (2015) Loss of EEGNetwork Efficiency Is
831 Related to Cognitive Impairment in Dementia With Lewy Bodies. *Mov Disord* 30:1785–1793.
832 <https://doi.org/10.1002/mds.26309>
- 833 67. Mehraram R, Kaiser M, Cromarty R, et al (2020) Weighted network measures reveal differences
834 between dementia types: An EEG study. *Hum Brain Mapp* 41:1573–1590.
835 <https://doi.org/10.1002/hbm.24896>
- 836 68. Dauwan M, Van Dellen E, Van Boxtel L, et al (2016) IC-03-05: EEG Directed Connectivity from
837 Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with
838 Alzheimer’s Disease And Controls. *Alzheimers Dement* 12:.
839 <https://doi.org/10.1016/j.jalz.2016.06.075>

- 840 69. Babiloni C, Del Percio C, Lizio R, et al (2018) Abnormalities of resting-state functional cortical
841 connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG
842 study. *Neurobiol Aging* 65:18–40. <https://doi.org/10.1016/j.neurobiolaging.2017.12.023>
- 843 70. Schumacher J, Peraza LR, Firbank M, et al (2019) Dysfunctional brain dynamics and their origin
844 in Lewy body dementia. *Brain* 142:1767–1782. <https://doi.org/10.1093/brain/awz069>
- 845 71. Lamoš M, Morávková I, Ondráček D, et al (2021) Altered Spatiotemporal Dynamics of the
846 Resting Brain in Mild Cognitive Impairment with Lewy Bodies. *Mov Disord* 36:2435–2440.
847 <https://doi.org/10.1002/mds.28741>
- 848 72. Bonanni L, Franciotti R, Onofri V, et al (2010) Revisiting P300 cognitive studies for dementia
849 diagnosis: Early dementia with Lewy bodies (DLB) and Alzheimer disease (AD). *Neurophysiol*
850 *Clin Neurophysiol* 40:255–265. <https://doi.org/10.1016/j.neucli.2010.08.001>
- 851 73. Rosenblum Y, Maidan I, Fahoum F, et al (2020) Differential changes in visual and auditory event-
852 related oscillations in dementia with Lewy bodies. *Clin Neurophysiol* 131:2357–2366.
853 <https://doi.org/10.1016/j.clinph.2020.06.029>
- 854 74. Rosenblum Y, Shiner T, Bregman N, et al (2022) Event-related oscillations differentiate between
855 cognitive, motor and visual impairments. *J Neurol* 269:3529–3540.
856 <https://doi.org/10.1007/s00415-021-10953-4>
- 857 75. Massa F, Meli R, Grazzini M, et al (2020) Utility of quantitative EEG in early Lewy body disease.
858 *Parkinsonism Relat Disord* 75:70–75. <https://doi.org/10.1016/j.parkreldis.2020.05.007>
- 859 76. Schumacher J, Taylor J-P, Hamilton CA, et al (2020) Quantitative EEG as a biomarker in mild
860 cognitive impairment with Lewy bodies. *Alzheimers Res Ther* 12:.
861 <https://doi.org/10.1186/s13195-020-00650-1>
- 862 77. Schumacher J, Taylor J-P, Hamilton CA, et al (2021) In vivo nucleus basalis of Meynert
863 degeneration in mild cognitive impairment with Lewy bodies. *NeuroImage Clin* 30:102604.
864 <https://doi.org/10.1016/j.nicl.2021.102604>
- 865 78. Babiloni C, Del Percio C, Lizio R, et al (2018) Abnormalities of Resting State Cortical EEG
866 Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body
867 Diseases. *J Alzheimers Dis* 62:247–268. <https://doi.org/10.3233/jad-170703>
- 868 79. Babiloni C, Del Percio C, Pascarelli MT, et al (2019) Abnormalities of functional cortical source
869 connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with
870 mild cognitive impairment due to Alzheimer's and Lewy body diseases. *Neurobiol Aging* 77:112–
871 127. <https://doi.org/10.1016/j.neurobiolaging.2019.01.013>
- 872 80. Yu M, Gouw AA, Hillebrand A, et al (2016) Different functional connectivity and network
873 topology in behavioral variant of frontotemporal dementia and Alzheimer's disease: an EEG
874 study. *Neurobiol Aging* 42:150–162. <https://doi.org/10.1016/j.neurobiolaging.2016.03.018>
- 875 81. Franciotti R, Moretti DV, Benussi A, et al (2022) Cortical network modularity changes along the
876 course of frontotemporal and Alzheimer's dementing diseases. *Neurobiol Aging* 110:37–46.
877 <https://doi.org/10.1016/j.neurobiolaging.2021.10.016>
- 878 82. Bonanni L, Moretti D, Benussi A, et al (2021) Hyperconnectivity in Dementia Is Early and Focal
879 and Wanes with Progression. *Cereb Cortex* 31:97–105. <https://doi.org/10.1093/cercor/bhaa209>

- 880 83. Moguilner S, Birba A, Fittipaldi S, et al (2022) Multi-feature computational framework for
881 combined signatures of dementia in underrepresented settings. *J Neural Eng* 19:046048.
882 <https://doi.org/10.1088/1741-2552/ac87d0>
- 883 84. Babiloni C, Lopez S, Del Percio C, et al (2020) Resting-state posterior alpha rhythms are
884 abnormal in subjective memory complaint seniors with preclinical Alzheimer’s neuropathology
885 and high education level: the INSIGHT-preAD study. *Neurobiol Aging* 90:43–59.
886 <https://doi.org/10.1016/j.neurobiolaging.2020.01.012>
- 887 85. Dauwan M, Van Der Zande JJ, Van Dellen E, et al (2016) Random forest to differentiate dementia
888 with Lewy bodies from Alzheimer’s disease. *Alzheimers Dement Diagn Assess Dis Monit* 4:99–
889 106. <https://doi.org/10.1016/j.dadm.2016.07.003>
- 890 86. Li M, Wang Y, Lopez-Naranjo C, et al (2022) Harmonized-Multinational qEEG norms
891 (HarMNqEEG). *NeuroImage* 256:119190. <https://doi.org/10.1016/j.neuroimage.2022.119190>
- 892